Abstract: A combination of gonadotrophins and growth hormone is useful for treating infertility in higher mammals and humans since the probability of pregnancy is enhanced. In the treatment, gonadotrophins and growth hormone are injected separately, or a combined preparation containing both of these active substances may be used.

Abstract: A DNA sequence containing a ribosome binding site with a SD sequence AGGA and a start codon ATG, comprising a nucleotide sequence having the formula Y.sub.1 . . . Y.sub.m ZVAGGA X.sub.1, X.sub.2 . . . X.sub.n ATG wherein Y.sub.1 . . . Y.sub.m represents a promoter with one or more restriction enzyme sites, m being an integer corresponding to the number of base pairs in the promoter, each X, Y, Z and V is A, T, C or G; n is 9 to 13, and the sequence X.sub.1 . . . X.sub.n cannot contain a start codon.

Abstract: An injection apparatus has a jacket having a front end and a cartridge for containing a liquid having a rubber membrane closing a front end of the cartridge at the front end of the jacket. A double-ended needle is held in a needle holder such that both ends thereof are exposed and oriented, one end at the membrane for piercing the membrane to obtain the liquid from the cartridge, and the opposite end for injecting the liquid. First cooperative threads on a cap and the jacket are for screwing the cap onto the jacket and unscrewing the cap therefrom, the first cooperative threads having a first pitch and a first rotational hand.

Abstract: Human growth hormone is used for the treatment of individuals who are intoxicated with poisonous substances of the type which is degraded in the liver by microsomal enzymes, such as hexobarbiturates or alcohol.

Abstract: Production of a high purity concentrate of the antihemophilic Factor VIII (AHF) by precipitation of an aqueous solution of cryoprecipitate from blood plasma in a first step with such an amount of polyethylene glycol (PEG), preferably about 4% by weight, as will precipitate a substantial amount of the present fibrinogen, subjecting the fibrinogen-free solution to a second precipitation step with preferably about 12% by weight of PEG in the presence of a salting-in agent, such as an amino acid, in particular lysine or arginine, or a carbohydrate, and then recovering the precipitate with a concentrated content of the present Factor VIII. The obtained Factor VIII concentrate with a very low content of immunoglobulins and other plasma proteins has a solubility in an aqueous injection medium of 45 to 500 units/ml and a high specific activity of up to 50 units/mg protein.